The FDA has approved tremelimumab (Imjudo, AstraZeneca) in combination with durvalumab (Imfinzi, AstraZeneca) for the treatment of adults with unresectable hepatocellular carcinoma.
This novel dose and combination schedule is called the STRIDE regimen (Single Tremelimumab Regular Interval Durvalumab). The approval was based on positive results from the HIMALAYA Phase III trial, where patients on the STRIDE regimen experienced a 22% reduction in the risk of death versus